Stock surges as FDA recognizes potential of innovative opioid

  • Ensysce Biosciences shares up 39% on FDA Breakthrough Designation for PF614-MPAR
  • Stock currently at $1.58, down 80% over the last 52 weeks
  • Ensysce developing opioids to treat pain with technology to prevent abuse and overdose
  • Phase 1 study shows PF614-MPAR delivers oxycodone appropriately in low doses but reduces delivery in high doses

Ensysce Biosciences saw a significant boost in its shares, rising 39%, after the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for its PF614-MPAR opioid. The stock, currently priced at $1.58, has experienced a decline of 80% over the past year. Ensysce is focused on developing opioids for pain management, utilizing technology designed to prevent drug abuse and overdose. In a Phase 1 study, PF614-MPAR demonstrated the ability to deliver oxycodone effectively in low doses, while reducing delivery in high doses, which could help mitigate the risk of overdose.

Public Companies: Ensysce Biosciences (N/A)
Private Companies:
Key People:

Factuality Level: 8
Justification: The article provides factual information about Ensysce Biosciences receiving Breakthrough Therapy Designation for its PF614-MPAR opioid from the FDA. It also mentions the recent stock price and volume. The article includes information about Ensysce’s development of opioids to prevent drug abuse and overdose, as well as the results of a Phase 1 study. However, the article lacks in-depth analysis and context, and it does not provide any opposing viewpoints or potential risks associated with the opioid.

Noise Level: 7
Justification: The article provides some relevant information about Ensysce Biosciences and its opioid product, but it lacks in-depth analysis, scientific rigor, and intellectual honesty. It does not explore the long-term trends or antifragility of the company’s technology. The article also does not hold powerful people accountable or provide actionable insights or solutions. Overall, it contains some noise and filler content.

Financial Relevance: Yes
Financial Markets Impacted: Ensysce Biosciences

Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: The news article pertains to a financial company, Ensysce Biosciences, and the FDA granting Breakthrough Therapy Designation for its opioid. There is no mention of an extreme event.

Reported publicly: www.marketwatch.com